by S.W. Clarke, Dr. C. Bailey, L. Ellison, C. Entwisle, Dr. K. Dalton, Dr. S. Hill, A. McIlgorm, N. Nath, W. Roy, and J.L. Halsall
Volume 8, Issue 1 (Spring 2009)
ImmBio’s lead development candidate is an influenza vaccine based on the ImmunoBody® platform technology. An ImmunoBody is a fusion of a selected immuno-dominant antigen with a cell-binding domain — the Fc fragment of human IgG1. The use of recombinant Fc fusion proteins is well documented where it can help solubilize hydrophobic proteins, provide a handle for easy detection and purification, as well as improve half-life…
Citation:
Clarke SW et al. Preparation of Haemagglutinin – lgG1 Fc Fusion Proteins in Insect Cells and Evaluation as Influenza Vaccines. BioProcess J, 2009; 8(1): 24-29. http://dx.doi.org/10.12665/J81.Clarke